- Technology Management
- For Industry - Technology Available for Licensing
- Contact Technology Management
- old pages
- A Modern Approach to Wing Warp for Aircraft Control
- Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
- Compositions and Methods for Treating and Diagnosing Hepatoma
- Vaccine Compositions and Methods That Increase Safety of Anti-Viral Vaccination Without Loss of Efficacy
- Automatic Pressure-Locking Valve Prevents CSF Loss and Herniation During Lumbar Puncture When Intracranial Pressure Is Elevated.
- Immortal Differentiated Type II Lung Epithelial Cell Line (T7)
- Human A Rapid, Reliable Bedside Diagnostic Method For Accurately Determining Feeding Tube Placement In Respiratory Tract, Stomach, Or Small Bowel Of Patients Prior to Enteral Nutrient Administration.
- Human Natural Killer Cell Line - NK 3.3:
- Factor IXa Protease Helix-330 (Region 1)
- In Vitro Method for Concerted Integration of Donor DNA Molecules Into Target DNA Using Retroviral Integrase and a Procedure for Evaluation of Donor DNA Integration.
- SRCAP: A Novel Transcription Protein Having Therapeutic Target and Diagnostic Target Product Development Potential.
- C-Terminal Binding Protein Interacting Protein (CtIP):
- Novel Anti-Coagulation Therapeutics: Agents That Effectively Inhibit Binding of Factor VIIIa (Region 3) With Factor IXa (Region 2) Without Activating Factor X.
- Genetically Modified Activated Protein C with Reduced Anticoagulant Properties
- C22: A Conditionally Immortalized Mouse Clara Cell Line
Genetically Modified Activated Protein C with Reduced Anticoagulant Properties
Inventor: Dr. Alireza R. Rezaie and Dr. Likui Yang
Researchers have recently discovered (in vitro) a novel form of activated protein C ("APC") which may be a potentially safer drug for treating severe sepsis in patients who experience a higher incidence of bleeding due to the anticoagulant function of APC. Researchers are proposing studies to further develop this therapeutic agent in vivo. This novel form of APC has been genetically engineered ("mAPC"). Unlike known forms of APC (such as Xigris®), this modified molecule retains the anti-inflammatory activity but none of the anti-coagulant effects. The inventors were also able to show that mAPC retains important physiological characteristics such as lack of apoptosis (cell death) in vitro and normal binding to endothelia cells.
Recently, recombinant APC has been approved as a drug for treating severe sepsis patients. There is growing evidence suggesting that the beneficial effect of APC in severe sepsis is separate from its anticoagulant effect and is, at least partially, attributed to its direct protective signaling effect in endothelium. Nevertheless, a major drawback of APC is the increased incidence of bleeding in ~2% of the treated patients. Therefore, there is an urgent need for APC variants with diminished anticoagulant activity while still retaining their cytoprotective effects.
This new invention retains the protective anti-inflammatory and anti-apoptotic properties of wild type APC, but lacks the anticoagulant properties responsible for excessive bleeding in some individuals who receive APC treatment for conditions such as septic shock.
Keywords: Activated Protein C, APC, anti-coagulant effects (Lack of), anti-apoptotic, cytoprotective, anti-inflammatory
License and/or Other Collaborative Research Opportunities: Available
Reference Number: SLU 06-030
Additional Information: Available under Confidentiality Agreement